Market Closed -
Euronext Paris
11:35:24 2024-04-26 EDT
|
5-day change
|
1st Jan Change
|
1.024
EUR
|
+0.59%
|
|
-4.66%
|
-20.50%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
9.242
|
7.367
|
24.29
|
67.65
|
48.45
|
32.98
|
32.98
|
-
|
Enterprise Value (EV)
1 |
3.288
|
0.1364
|
15.13
|
64.02
|
48.45
|
41.49
|
29.58
|
33.08
|
P/E ratio
|
-1.44
x
|
3.74
x
|
-12.4
x
|
-10.6
x
|
-
|
-7.31
x
|
-6.83
x
|
-5.69
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
46.2
x
|
-
|
-
|
96.6
x
|
9.14
x
|
9.02
x
|
7.17
x
|
4.64
x
|
EV / Revenue
|
16.4
x
|
-
|
-
|
91.5
x
|
9.14
x
|
9.02
x
|
6.43
x
|
4.66
x
|
EV / EBITDA
|
-0.47
x
|
-0.05
x
|
-5.14
x
|
-11
x
|
-
|
-8.22
x
|
-5.19
x
|
-3.94
x
|
EV / FCF
|
-0.55
x
|
-0.03
x
|
-
|
-9.33
x
|
-
|
-7.83
x
|
-4.41
x
|
-3.48
x
|
FCF Yield
|
-183%
|
-2,895%
|
-
|
-10.7%
|
-
|
-12.8%
|
-22.7%
|
-28.7%
|
Price to Book
|
2.37
x
|
1.04
x
|
3.36
x
|
6.34
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
18,861
|
21,862
|
24,557
|
27,668
|
28,137
|
32,205
|
32,205
|
-
|
Reference price
2 |
0.4900
|
0.3370
|
0.9890
|
2.445
|
1.722
|
1.024
|
1.024
|
1.024
|
Announcement Date
|
19-01-24
|
20-03-10
|
21-02-25
|
22-04-28
|
23-03-29
|
24-03-11
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
0.2
|
-
|
-
|
0.7
|
5.3
|
4.6
|
4.6
|
7.1
|
EBITDA
1 |
-7.013
|
-2.512
|
-2.946
|
-5.833
|
-
|
-4
|
-5.7
|
-8.4
|
EBIT
1 |
-7.1
|
-2.5
|
-3
|
-5.952
|
-4.109
|
-3.4
|
-6.3
|
-9
|
Operating Margin
|
-3,550%
|
-
|
-
|
-850.29%
|
-77.53%
|
-73.91%
|
-136.96%
|
-126.76%
|
Earnings before Tax (EBT)
|
-6.305
|
1.887
|
-1.886
|
-5.822
|
-
|
-
|
-
|
-
|
Net income
1 |
-6.3
|
1.8
|
-1.9
|
-5.822
|
-4.206
|
-3.5
|
-6.5
|
-9
|
Net margin
|
-3,150%
|
-
|
-
|
-831.71%
|
-79.36%
|
-76.09%
|
-141.3%
|
-126.76%
|
EPS
2 |
-0.3400
|
0.0900
|
-0.0800
|
-0.2300
|
-
|
-0.1400
|
-0.1500
|
-0.1800
|
Free Cash Flow
1 |
-6.011
|
-3.95
|
-
|
-6.858
|
-
|
-4.2
|
-6.7
|
-9.5
|
FCF margin
|
-3,005.5%
|
-
|
-
|
-979.71%
|
-
|
-91.3%
|
-145.65%
|
-133.8%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-01-24
|
20-03-10
|
21-02-25
|
22-04-28
|
23-03-29
|
24-03-11
|
-
|
-
|
Fiscal Period: December |
2019 S1
|
2023 S1
|
---|
Net sales
1 |
-
|
2.13
|
EBITDA
|
-
|
-
|
EBIT
|
-1.45
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
1 |
-
|
-2.25
|
Net margin
|
-
|
-105.63%
|
EPS
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
19-09-06
|
23-09-26
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.1
|
Net Cash position
1 |
5.95
|
7.23
|
9.15
|
3.63
|
-
|
0.1
|
3.4
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-0.0119
x
|
Free Cash Flow
1 |
-6.01
|
-3.95
|
-
|
-6.86
|
-
|
-4.2
|
-6.7
|
-9.5
|
ROE (net income / shareholders' equity)
|
-99.1%
|
35.2%
|
-
|
-67.3%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
0.2100
|
0.3200
|
0.2900
|
0.3900
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-0.3200
|
-0.1900
|
-0.0300
|
-0.2600
|
-
|
-
|
-
|
-
|
Capex
1 |
0.01
|
-
|
-
|
0.17
|
-
|
0.1
|
0.1
|
0.1
|
Capex / Sales
|
5%
|
-
|
-
|
23.71%
|
-
|
2.17%
|
2.17%
|
1.41%
|
Announcement Date
|
19-01-24
|
20-03-10
|
21-02-25
|
22-04-28
|
23-03-29
|
24-03-11
|
-
|
-
|
Last Close Price
1.024
EUR Average target price
10.5
EUR Spread / Average Target +925.39% Consensus |
1st Jan change
|
Capi.
|
---|
| -20.50% | 35.21M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.73B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|